Ad
related to: guillain barré syndrome clinical trials treatment
Search results
Results from the WOW.Com Content Network
Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the peripheral nervous system. [3] Typically, both sides of the body are involved, and the initial symptoms are changes in sensation or pain often in the back along with muscle weakness, beginning in the feet and hands, often spreading to the arms and upper body. [3]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Neurology. Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired autoimmune disease of the peripheral nervous system characterized by progressive weakness and impaired sensory function in the legs and arms. [1] The disorder is sometimes called chronic relapsing polyneuropathy (CRP) or chronic inflammatory demyelinating ...
An estimated 3,000 to 6,000 people develop Guillain-Barre syndrome in the U.S. each year — either after being infected by a virus or linked to a vaccination — and it’s more common in older ...
Specialty. Neurology. Acute motor axonal neuropathy (AMAN) is a variant of Guillain–Barré syndrome. It is characterized by acute paralysis and loss of reflexes without sensory loss. Pathologically, there is motor axonal degeneration with antibody-mediated attacks of motor nerves and nodes of Ranvier. [citation needed]
Also anti-GM1 IgG has been identified in Guillain–Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy. [19] while controlled studies failed to find any significant association with Motor neuron disease. [20] IgA. IgA to gangliosides have been observed in Guillain–Barré syndrome. IgM. IgM antibodies have been ...
Treatment. Immunotherapy. [2] Bickerstaff brainstem encephalitis is a rare inflammatory disorder of the central nervous system, [3] first described by Edwin Bickerstaff in 1951. [4][5] It may also affect the peripheral nervous system, and has features in common with both Miller Fisher syndrome and Guillain–Barré syndrome.
Paraneoplastic syndrome, Guillain-Barré syndrome, diabetes, amyloidosis, Sjogren's syndrome, and Morvan syndrome. Autoimmune autonomic ganglionopathy is a type of immune-mediated autonomic failure that is associated with antibodies against the ganglionic nicotinic acetylcholine receptor present in sympathetic, parasympathetic, and enteric ganglia.
Ad
related to: guillain barré syndrome clinical trials treatment